Valvular & structural heart diseaseSecondary analysis
TRISCEND II
- Secondary analysis of the TRISCEND II randomised trial
- multicentre
- prospective
- 2:1 randomisation
- independent echocardiographic core laboratory
Authors' conclusion
One-year echocardiographic outcomes from the TRISCEND II trial demonstrated that near elimination of TR following TTVR is associated with reduced venous congestion, RV reverse remodeling, and significant improvements in forward stroke volume and cardiac output.
Study context
- Population
- Patients with severe, symptomatic tricuspid regurgitation
- Participants
- 400 patients
- Comparison
- Transcatheter tricuspid valve replacement (TTVR) vs medical therapy
- TTVRn = 267
- Controln = 133reference
- Primary endpoint
- Reduction in TR severity from baseline (secondary echocardiographic endpoint of the trial)
- Follow-up
- Discharge
Primary result
As reported in the abstract
Mild TR at discharge
TTVR
95.5%
Further findings
Mild TR (paired analysis, baseline to 1 year)
Mean inferior vena cava diameter · baseline to 1 year
- Decreased significantly more with TTVR, normal breathing
- P < 0.001
- Decreased significantly more with TTVR, forced inhalation
- P = 0.038
Right ventricular (RV) size and function · baseline to 1 year
- Greater improvement in diastolic RV size with TTVR
- P < 0.05
- Larger decrease in RV systolic function with TTVR, consistent with reduced preload
- P < 0.001
RV stroke volume and cardiac output
- Increased significantly with TTVR, not in control
- P < 0.001
Original publication
TRISCEND II. JACC Cardiovasc Imaging. Published 18 July 2026. doi:10.1016/j.jcmg.2026.05.019
Summarised from the published abstract; every number is checked against it